Abstract
Emergence of novel SARS-CoV-2 lineages are under the spotlight of the media, scientific community and governments. Recent reports of novel variants in the United Kingdom, South Africa and Brazil (B.1.1.28-E484K) have raised intense interest because of a possible higher transmission rate or resistance to the novel vaccines. Nevertheless, the spread of B.1.1.28 (E484K) and other variants in Brazil is still unknown. In this work, we investigated the population structure and genomic complexity of SARS-CoV-2 in Rio Grande do Sul, the southernmost state in Brazil. Most samples sequenced belonged to the B.1.1.28 (E484K) lineage, demonstrating its widespread dispersion. We were the first to identify two independent events of co-infection caused by the occurrence of B.1.1.28 (E484K) with either B.1.1.248 or B.1.91 lineages. Also, clustering analysis revealed the occurrence of a novel cluster of samples circulating in the state (named VUI-NP13L) characterized by 12 lineage-defining mutations. In light of the evidence for E484K dispersion, co-infection and emergence of VUI-NP13L in Rio Grande do Sul, we reaffirm the importance of establishing strict and effective social distancing measures to counter the spread of potentially more hazardous SARS-CoV-2 strains.
Highlights
The novel variant B.1.1.28 (E484K) previously described in Rio de Janeiro is currently spread across the southernmost state of Brazil;
The novel variant VUI-NP13L was also identified by causing a local outbreak in Rio Grande do Sul;
B.1.1.28 (E484K) is able to establish successful coinfection events co-occurring simultaneously with different lineages of SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was developed in the frameworks of Rede Corona-omica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP = 01.20.0029.000462/20, CNPq = 404096/2020-4). The study was also supported by Corona-omica-RJ (FAPERJ = E-26/210.179/2020). A.T.R.V. is supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (303170/2017-4) and FAPERJ (E-26/202.903/20). F.R.S is a CNPq fellow (302668/2018-7). R.S.F.J is a recipient of a graduate fellowship from CNPq. A.P.L and L.F.B are granted a post-doctoral scholarship (DTI-A) from CNPq. J.S.L., M.D., A.K.E.A., K.S. are recipients of CAPES scholarships; F.H.H., B.H., V.G. and M.F. are supported by CNPq grants.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1. This study was approved by the National Committee of Research Ethics and the Institutional Ethical Review Board of the Universidade de Feevale (protocol number: 33202820.7.1001.5348), following Brazilian regulations and international ethical standards. 2. Decision made: ethical approval was given.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
NGS data generated in our study is publicly available in Gisaid (www.gisaid.org), and the access identifiers are listed in Supplementary Material.
